Zai

Zai Lab Announces Financial Results for Second-half and Full-year 2020

Retrieved on: 
Monday, March 1, 2021
Financial markets, Finance, Money, Hong Kong Exchanges and Clearing, Hang Seng Index, Zai, NASDAQ, Midcap

ET

Key Points: 
  • ET
    SHANGHAI and SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today reported financial results for the second half and full year of 2020, along with corporate updates.
  • 2020 was another year of great accomplishment for Zai Lab, said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.
  • Zai Lab has been added to the Hang Seng Composite MidCap Index as of December 7, 2020.
  • Zai Lab will host a live conference call and webcast on March 1, 2021 at 8:00 a.m.

Turning Point and Zai Lab Broaden Collaboration

Retrieved on: 
Monday, January 11, 2021
Turning Point, Zai

In addition, Turning Point will have the right of first negotiation to develop and commercialize an oncology drug candidate discovered by Zai Lab.

Key Points: 
  • In addition, Turning Point will have the right of first negotiation to develop and commercialize an oncology drug candidate discovered by Zai Lab.
  • This agreement builds on Zai Lab and Turning Points existing relationship under the exclusive licensing agreement announced by the companies in July 2020, under which Zai Lab gained the exclusive right to develop and commercialize Turning Points lead drug candidate, repotrectinib, inGreater China.
  • We have great confidence in Zai Lab as our partner to advance this important drug candidate in a key region of the world.
  • Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer ofZai Lab, said, Turning Point has assembled a formidable pipeline of next-generation oncology target therapies, and we are very pleased to broaden our global collaboration and strategic partnership.

Turning Point and Zai Lab Broaden Collaboration

Retrieved on: 
Monday, January 11, 2021
Turning Point, Zai

In addition, Turning Point will have the right of first negotiation to develop and commercialize an oncology drug candidate discovered by Zai Lab.

Key Points: 
  • In addition, Turning Point will have the right of first negotiation to develop and commercialize an oncology drug candidate discovered by Zai Lab.
  • This agreement builds on Zai Lab and Turning Points existing relationship under the exclusive licensing agreement announced by the companies in July 2020, under which Zai Lab gained the exclusive right to develop and commercialize Turning Points lead drug candidate, repotrectinib, inGreater China.
  • We have great confidence in Zai Lab as our partner to advance this important drug candidate in a key region of the world.
  • Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer ofZai Lab, said, Turning Point has assembled a formidable pipeline of next-generation oncology target therapies, and we are very pleased to broaden our global collaboration and strategic partnership.

Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group

Retrieved on: 
Monday, January 4, 2021
Expense, Intellectual property law, Patent law, Royalty payment, Zai

Upon Zai Labs regulatory approval, anticipated in the first half of 2021, Paratek will receive a $6.0 million milestone payment.

Key Points: 
  • Upon Zai Labs regulatory approval, anticipated in the first half of 2021, Paratek will receive a $6.0 million milestone payment.
  • All milestone payments under the Zai Lab License and Collaboration Agreement are excluded from the R-Bridge Loan and are retained by the Company.
  • The R-Bridge Loan is non-recourse to the Company other than the Zai Lab royalties and the U.S. NUZYRA revenue interest.
  • Founded in2014, CBC has a strong team of investment, healthcare and portfolio management professionals based across Singapore, Shanghai, Beijing, Hong Kong and New York.

Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 30, 2020
Financial markets, Hong Kong Exchanges and Clearing, Finance, Zai, Money

SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 11:40 a.m. EST.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 11:40 a.m. EST.
  • The live webcast of the presentation and breakout session will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

Retrieved on: 
Tuesday, December 29, 2020
Finance, Financial markets, Money, National Healthcare Security Administration, State Council of the People's Republic of China, National Roller Derby League, Hong Kong Exchanges and Clearing, Reimbursement, Zai

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).
  • The inclusion of our first NMPA-approved medicine, ZEJULA, in the NRDL is an important step in achieving that mission.
  • NHSA reimbursement will help make ZEJULA affordable to many patients in need across China, said William Liang, Chief Commercial Offer.
  • Zai Lab also conducted a Phase I pharmacokinetic (PK) study of ZEJULA in Chinese patients with ovarian cancer.

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

Retrieved on: 
Monday, December 28, 2020
Zai

Cullinan Pearl is also eligible to receive high-single-digit to low-teen tiered royalties based on annual net sales of CLN-081 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.

Key Points: 
  • Cullinan Pearl is also eligible to receive high-single-digit to low-teen tiered royalties based on annual net sales of CLN-081 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
  • Zai Lab obtains the exclusive right to develop, manufacture and commercialize CLN-081 in Greater China.
  • Zai Lab is the ideal partner for innovative drug development and commercialization in Greater China, and we are excited to be collaborating with them on CLN-081, said Owen Hughes, Chief Executive Officer of Cullinan Oncology.
  • We look forward to working with Zai to initiate development of CLN-081 in China as soon as possible.

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Retrieved on: 
Wednesday, October 28, 2020
Financial markets, Finance, Hong Kong Exchanges and Clearing, Zai, Money

SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that management from Zai Lab will present at the following upcoming virtual investor conferences in November.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that management from Zai Lab will present at the following upcoming virtual investor conferences in November.
  • Details are as follows:
    A live webcast of the Jefferies Virtual London Healthcare Conference presentation will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
  • Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas.

Zai Lab Announces Full Exercise of the Over-allotment Option

Retrieved on: 
Friday, October 9, 2020
Financial markets, Finance, Hong Kong Exchanges and Clearing, Forward-looking statement, Zai, Money

SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the over-allotment option.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the over-allotment option.
  • The Listing Committee of the Hong Kong Stock Exchange has granted the approval for the listing of and permission to deal in the Over-allotment Shares.
  • This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding business strategy, plans and objectives for future operations.
  • These forward-looking statements should not be relied upon as representing Zai Labs views as of any date subsequent to the date of this press release.

Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020

Retrieved on: 
Thursday, September 3, 2020
Zai, European Society for Medical Oncology, ESMO

SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.
  • Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas.
  • Zai Labs vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.
  • For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.